Cell therapy procedure using anti-inflammatory macrophage M2 can potentially reduce Clinical Score in animals with Experimental Autoimmune Encephalomyelitis: A preclinical systematic review and meta-analysis study

被引:4
作者
Abdolmaleki, Amir [1 ]
Kondori, Bahman Jalali [2 ,3 ]
Raei, Mehdi [4 ]
Ghaleh, Hadi Esmaeili Gouvarchin [5 ]
机构
[1] Baqiyatallah Univ Med Sci, Med Sch, Dept Anat Sci, Tehran, Iran
[2] Baqiyatallah Univ Med Sci, Fac Med, Dept Anat Sci, Tehran, Iran
[3] Baqiyatallah Univ Med Sci, Baqiyatallah Res Ctr Gastroenterol & Liver Dis BR, Tehran, Iran
[4] Baqiyatallah Univ Med Sci, Life Style Inst, Hlth Res Ctr, Tehran, Iran
[5] Baqiyatallah Univ Med Sci, Appl Virol Res Ctr, Med Sch, Tehran, Iran
关键词
autoimmune; cell therapy; EAE; encephalomyelitis; experimental; macrophage M2; meta-analysis; multiple sclerosis; systematic review; ADOPTIVE TRANSFER; INJECTION; SUPPRESS; MODELS; INJURY;
D O I
10.1111/fcp.12844
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Macrophage M2 (MP2)-based cell therapy is a novel medicinal treatment for animals with Experimental Autoimmune Encephalomyelitis (EAE) as an experimental model of multiple sclerosis (MS). This systematic review and meta-analysis study was designed to assess the overall therapeutic effects of MP2 cell therapy on Clinical Score and motor impairment in EAE-induced animals. All experiments on MP2 cell therapy in animals with EAE were gathered (by October 2, 2022) from English (PubMed, Scopus, WoS, Science Direct, and ISC) and Persian (MagIran and SID) databases. The searching strategy was designed using "Experimental Autoimmune Encephalomyelitis," "Multiple Sclerosis," and "Macrophage M2" keywords. Following primary and secondary screenings, eligible papers were selected based on the PRISMA 2020 guideline, and the study quality was assessed using the Animal Research: Reporting of In Vivo Experiments (ARRIVE) checklist. The difference in means of Clinical Score (score 0-5) as the effect size (ES) was analyzed based on the random effect model (CMA software, v.2). Subgrouping (EAE phases of Onset, Peak, and Recovery) was applied, and I-2 index was used to assess the heterogeneity index. Publication bias and sensitivity indices were also evaluated. P < 0.05 was considered significant, and the confidence interval (CI) was determined 95%. Among 22 gathered papers, medium to high quality studies were selected for meta-analysis. Difference in means, P value, and I-2 for Onset, Peak, and Recovery phases were 0.082 (CI95%: -0.323-0.159, P value: 0.504, I-2: 67.961%), -0.606 (CI95%: -1.518 to -0.305, P value: 0.192, I-2: 96.070%), and -1.103 (CI95%: -1.390 to -0.816, P value: 0.000, I-2: 30.880%), respectively and Overall Effect was found -0.509 (CI95%: -0.689 to -0.328, P value < 0.001). Also, P value (two-tailed) indices for publication bias were 0.366 and 0.583 for Egger's regression intercept and Begg rank correlation, respectively. The P value for sensitivity was detected 0.003. Cell therapy procedure using MP2 can potentially alleviate the Clinical Scores Index and correct the motor defects in Recovery phase of EAE animals. In healthy mice, the brain and myelin surrounding neurons are in a healthy and physiological state (1). To evaluate MS in humans, it is necessary to model this type of disease in animals using EAE procedure through subcutaneous injection of CFA, MOG(35-55), MT, and Pert. Thus, inflammation and autoimmunity occur, which finally lead to myelin destruction and motor symptoms (2). By aspiration of progenitor cells available in bone marrow, the MP2 can be isolated and cultured. By activation of these types of cells, a rich collection of MP2 can be prepared for the cell-therapy process (3). After injection through the tail vein or intra-peritoneal procedure, these cells can be located in CNS through crossing from the BBB. They begin their anti-inflammatory activities and help repair the damaged myelin (4). Eventually, the clinical symptoms can be modified considerably, and the animal motor function improves (5). CFA, complete Freund's adjuvant; MOG(35-55), myelin oligodendrocyte glycoprotein; MT, Mycobacterium tuberculosis; Pert, pertussis; EAE, Experimental Autoimmune Encephalomyelitis; BM, bone marrow; MP2, macrophage M2; and BBB, blood brain barrier.
引用
收藏
页码:215 / 225
页数:11
相关论文
共 30 条
[21]   Type II-activated macrophages suppress the development of experimental autoimmune encephalomyelitis [J].
Tierney, Joanna B. ;
Kharkrang, Marie ;
La Flamme, Anne Camille .
IMMUNOLOGY AND CELL BIOLOGY, 2009, 87 (03) :235-240
[22]   De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis [J].
Tompkins, SM ;
Padilla, J ;
Dal Canto, MC ;
Ting, JPY ;
Van Kaer, L ;
Miller, SD .
JOURNAL OF IMMUNOLOGY, 2002, 168 (08) :4173-4183
[23]   Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition [J].
Walton, Clare ;
King, Rachel ;
Rechtman, Lindsay ;
Kaye, Wendy ;
Leray, Emmanuelle ;
Marrie, Ruth Ann ;
Robertson, Neil ;
La Rocca, Nicholas ;
Uitdehaag, Bernard ;
van der Mei, Ingrid ;
Wallin, Mitchell ;
Helme, Anne ;
Napier, Ceri Angood ;
Rijke, Nick ;
Baneke, Peer .
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (14) :1816-1821
[24]   Intraperitoneal injection (IP), Intravenous injection (IV) or anal injection (AI)? Best way for mesenchymal stem cells transplantation for colitis [J].
Wang, Min ;
Liang, Cong ;
Hu, Hao ;
Zhou, Lin ;
Xu, Bing ;
Wang, Xin ;
Han, Ying ;
Nie, Yongzhan ;
Jia, Shuyun ;
Liang, Jie ;
Wu, Kaichun .
SCIENTIFIC REPORTS, 2016, 6
[25]   Reversible differentiation of pro- and anti-inflammatory macrophages [J].
Xu, Wei ;
Zhao, Xiwen ;
Daha, Mohamed R. ;
van Kooten, Cees .
MOLECULAR IMMUNOLOGY, 2013, 53 (03) :179-186
[26]   Progress in understanding the pathophysiology of multiple sclerosis [J].
Zephir, H. .
REVUE NEUROLOGIQUE, 2018, 174 (06) :358-363
[27]   Adoptive Transfer of Cytokine-Induced Immunomodulatory Adult Microglia Attenuates Experimental Autoimmune Encephalomyelitis in DBA/1 Mice [J].
Zhang, Xing-Mei ;
Lund, Harald ;
Mia, Sohel ;
Parsa, Roham ;
Harris, Robert A. .
GLIA, 2014, 62 (05) :804-817
[28]   Comparison of the characteristics of macrophages derived from murine spleen, peritoneal cavity, and bone marrow [J].
Zhao, Yan-long ;
Tian, Pu-xun ;
Han, Feng ;
Zheng, Jin ;
Xia, Xin-xin ;
Xue, Wu-jun ;
Ding, Xiao-ming ;
Ding, Chen-guang .
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2017, 18 (12) :1055-1063
[29]   Delivery Efficacy Differences of Intravenous and Intraperitoneal Injection of Exosomes: Perspectives from Tracking Dye Labeled and MiRNA Encapsulated Exosomes [J].
Zhou, Xueying ;
Li, Zhelong ;
Sun, Wenqi ;
Yang, Guodong ;
Xing, Changyang ;
Yuan, Lijun .
CURRENT DRUG DELIVERY, 2020, 17 (03) :186-194
[30]  
Zickri Maha Baligh, 2014, International Journal of Stem Cells, V7, P1, DOI 10.15283/ijsc.2014.7.1.1